the National Human Genome Research Institute (NHGRI), said he expects the larger comprehensive project to yield " an awful lot of discoveries. " " The project we're planning needs to be really bold and ambitious, " Collins said.
" Doing this on a small scale is not likely to be successful. " Not everyone agrees. " I think you'd probably get more bang for your buck if you do investigatordriven research than these megaprojects, " said Rene Bernards, Ph.D., head of the division of molecular carcinogenesis at the Netherlands Cancer Institute in Amsterdam.
Linking Mutations to Drugs
The cancer genome project originated when NCI director Andrew von Eschenbach, M.D., asked Hartwell and Eric Lander, Ph.D., director of the Broad Institute in Cambridge, Mass., to oversee a study of technology opportunities in cancer as part of von Eschenbach's plan to eliminate death and suffering from cancer by 2015.
From those discussions, Hartwell drafted a proposal for a biomarker project and Lander's group wrote the proposal for the cancer genome project. After Lander presented the project proposal to the National Cancer Advisory Board in February, the project moved forward quickly, with planners hoping to release several requests for applications (RFAs) to the outside scientifi c community as soon as possible. In late July, cancer experts from many different fi elds held a workshop in Washington, D.C., to lay out options for structuring a NEWS NEWS Human Cancer Genome Project Moving Forward Despite Some Doubts in Community pilot project, which should be up and running next year. An external scientifi c committee is now making decisions on issues like tumor focus, technology choices, and sample collection. The NCI and NHGRI have each committed $50 million to the pilot project.
The overall cancer genome project is driven in part by recent scientifi c fi ndings about how specifi c cancer-related mutations can affect drug response. These include the 2004 discovery that somatic mutations in the epidermal growth factor receptor (EGFR) gene in lung tumors can predict patient response to the drug gefi tinib (Iressa) and the 2003 discovery that mutations in the c-Kit gene can predict response to the drug imatinib (Gleevec).
These and other discoveries of novel mutations in cancer genes gave hope that large-scale sequencing of tumors will enable individualized drug therapy for existing drugs -and discovery of new drugs. At the same time, tumors don't arise just from gene mutations. Abnormal gene copy number; gene silencing through methylation and other epigenetic mechanisms; and gene translocations, amplifi cations, and deletions also contribute in various degrees, depending on the tumor. The cancer genome project will also analyze these phenomena. " Sequence is just one kind of information, " said Collins. " What we're trying to do here is to learn everything we possibly can from every kind of technology. " Still, mutation detection will probably be the single biggest part of the cancer
Lee Hartwell
Francis Collins genome project, according to planning documents. The NCAB report suggested a comprehensive genomic analysis of roughly 12,500 tumor samples -250 samples from each of 50 major cancer types. " As sequencing technology improves and costs fall, it should become possible to resequence all human genes in all samples, " reads the report.
A Worrisome Precedent?
Despite the $100 million commitment by two NIH institutes, some in the cancer research community are not yet convinced that large-scale sequencing of tumors will be worth the investment. " I think everyone would say, ' Yes, it would be useful to have the sequence, ' " said Stephen Elledge, Ph.D., a Harvard Medical School geneticist. " The real question is, if we have $1.5 billion in new cancer money, is that what we want to do with it? What's the quickest way to get a cure for the disease? "
A more limited sequencing effort, the Sanger Institute's Cancer Genome Project, has delivered mixed results. Begun in 2000, the project discovered the important BRAF mutations in melanoma, and several drug companies have now launched programs to fi nd BRAF kinase inhibitors. But the project recently sequenced breast cancers and found few recurring somatic mutations. Sanger researchers sequenced the coding regions of all 518 protein kinases in 25 breast cancers and breast cancer cell lines, but most of the primary breast cancers had no somatic kinase mutations at all. Resequencing of the mutated genes in 56 other breast cancer samples yielded only three more functional mutations. " The results suggest that there is no commonly point-mutated and activated protein kinase gene in invasive ductal breast cancer, " concluded the paper's authors.
The Sanger result " doesn't cause me any anxiety at all, " said Collins. " I think what it shows is that if one wants to undertake this kind of analysis, you do need large numbers of samples, and you need to survey very large numbers of genes. "
Others take away different lessons. " You're not going to fi nd all the gold in the kinases, " said Hartwell. " And maybe … you're not going to fi nd the gold in sequencing. I'm personally much more interested in rearrangements and meth ylation than I am in point mutations. "
For some, the Sanger results raised doubts about the genome project sequencing plans. " The question is, how much information can you really get from resequencing tumor samples? " said Elledge. " And will you be able to fi gure out the real stuff from the noise? And if you are, how will that translate into cures for cancer? "
A Functional Alternative?
A different approach -one that has received little attention in genome project planning but, according to several researchers, should be -is functional genomics. It's now possible to use " bar-coded " small-hairpin RNAs (shRNAs) to systematically knock out genes in human cells to determine their function, using the power of RNA interference. Until now, such large-scale knockouts had been possible only in model organisms. Using shRNA and cDNA (complementary DNA) " libraries, " one could, in theory, activate or knock out every gene to see if the cancer cells grow or die -and every phenotype in between -compared with normal cells, and then fi sh out the genes responsible.
" If we were to spend money on a functional genetic interaction map of the genome, including large-scale synthetic lethal screens, wouldn't we be getting a lot more value for our money? " asked Bernards. " More targeted, rather than brainless, sequencing. " Bernards pointed out that sequencing would miss many key cancer genes. " There's probably a whole range of spectacularly good cancer targets out there that are synthetic lethal with loss of Rb, loss of p53, loss of PTEN, " he said. " These genes may not be mutated in human cancer, and may not be amplifi ed, and therefore would completely stay below the radar screen of this resequencing effort. "
Elledge also argued for a functional genetics approach. " Look for genes which, when you interfere with them, kill cancer cells and not normal cells, " he said. " These aren't going to be genes that are mutant in tumors. "
The biggest limitation of this approach is that functional genetic screens can't yet be done in many cell lines, and not at all in primary tumor samples. " The question is, are they able to scale to the level that this particular project aims to achieve in terms of getting an encyclopedic view of the causes of cancer? " said Collins. " I think, at the moment, most of those approaches are generally only workable [in] a small number of cell lines. " Bernards disagreed. " If you spend the kind of money they wish to spend on cancer genome resequencing, we could make a functional interaction map of spectacular size, " he said.
The Case for Big Science
Besides differences over scientifi c approach, there is concern that the project will generate a momentum of its own, even if the pilot project delivers disappointing results, and then not add much of value. Elledge said many colleagues wanted to see an independent evaluation of the pilot project's data when it's done. " They felt that there needed to be some sort of ' go/no-go ' decision for whether or not these things should go forward, that shouldn't be made by the people doing the work, " he said. Hartwell agreed. " There should be independent assessment of its execution and progress, " he said.
Lander said that the NIH-based peer review process and annual Congressional scrutiny will provide effective oversight for that evaluation. " There should be no expectations of infi nite life for something like this, " he said. " The decisions for such a project have to be guided by data and productivity. "
The funding issue remains the biggest concern -and a legitimate one, Collins acknowledged. " The leadership of the NIH is equally concerned about not doing damage to the most critical part of our portfolio, which is the R01, " he said.
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Downloaded from https://academic.oup.com/jnci/article-abstract/97/18/1322/2521415 by guest on 30 December 2018 " At the same time, this is all very reminiscent of the debates that raged in the scientifi c community more than 15 years ago when the Human Genome Project was being debated. " Collins argued that the pilot project, if successful, should be able to generate the new funding. And, he added, R01 investigators will be greatly helped by the new data, just as they were by the Human Genome Project. " We should always … try to achieve the right balance between the investigator-initiated research, which will always be the majority of what we do, and then identifying specifi c examples of large-scale, highthroughput enterprises, which really can't be mounted by a single investigator, but which can empower everybody, " he said. " And when we see those, as we now do for the cancer genome, it would be irresponsible not to move forward as quickly as possible to make them come true. " -Ken Garber NEWS NEWS
